Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gourlet

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Regulatory Peptides|August 13, 1991
Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cordA Cauvin, P Robberecht, P De Neef, et al.
European Journal of Biochemistry|September 22, 1999
Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activationM G Juarranz, J Van Rampelbergh, P Gourlet, et al.
European Journal of Pharmacology|September 3, 1998
Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptorsP Gourlet, J Rathé, P De Neef, et al.
European Journal of Biochemistry|July 1, 1992
Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonistP Robberecht, P Gourlet, P De Neef, et al.
Peptides|January 1, 1995
Identification of a new chromogranin B fragment (314-365) in endocrine tumorsM C Woussen-Colle, P Gourlet, A Vandermeers, et al.
Peptides|January 1, 1997
The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclassP Gourlet, P Vertongen, A Vandermeers, et al.
Biochimica Et Biophysica Acta|July 22, 1991
The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranesP Gourlet, P De Neef, M C Woussen-Colle, et al.
Molecular Pharmacology|August 1, 1992
Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21P Robberecht, P Gourlet, P De Neef, et al.
FEBS Letters|July 29, 1991
The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranesP Robberecht, M C Woussen-Colle, P De Neef, et al.
European Journal of Biochemistry|January 30, 1991
Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranesP Gourlet, M C Woussen-Colle, P Robberecht, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Regulatory Peptides|August 13, 1991
Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cordA Cauvin, P Robberecht, P De Neef, et al.
European Journal of Biochemistry|September 22, 1999
Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activationM G Juarranz, J Van Rampelbergh, P Gourlet, et al.
European Journal of Pharmacology|September 3, 1998
Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptorsP Gourlet, J Rathé, P De Neef, et al.
European Journal of Biochemistry|July 1, 1992
Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonistP Robberecht, P Gourlet, P De Neef, et al.
Peptides|January 1, 1995
Identification of a new chromogranin B fragment (314-365) in endocrine tumorsM C Woussen-Colle, P Gourlet, A Vandermeers, et al.
Peptides|January 1, 1997
The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclassP Gourlet, P Vertongen, A Vandermeers, et al.
Biochimica Et Biophysica Acta|July 22, 1991
The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranesP Gourlet, P De Neef, M C Woussen-Colle, et al.
Molecular Pharmacology|August 1, 1992
Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21P Robberecht, P Gourlet, P De Neef, et al.
FEBS Letters|July 29, 1991
The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranesP Robberecht, M C Woussen-Colle, P De Neef, et al.
European Journal of Biochemistry|January 30, 1991
Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranesP Gourlet, M C Woussen-Colle, P Robberecht, et al.
Pageof 5